1-20 of 41
Fortunato Ciardiello
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Antitumor Efficacy of Dual Blockade with Encorafenib + Cetuximab in Combination with Chemotherapy in Human BRAFV600E-Mutant Colorectal Cancer

Stefania Napolitano, Melanie Woods, Hey Min Lee, Vincenzo De Falco, Giulia Martini, Carminia Maria Della Corte, Erika Martinelli, Vincenzo Famiglietti, Davide Ciardiello, Amanda Anderson, Natalie Wall Fowlkes, Oscar Eduardo Villareal, Alexey Sorokin, Preeti Kanikarla, Olu Coker, Van Morris, Lucia Altucci, Josep Tabernero, Teresa Troiani, Fortunato Ciardiello, Scott Kopetz
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (12): 2299–2309.
https://doi.org/10.1158/1078-0432.CCR-22-3894
Published: 13 June 2023
View articletitled, Antitumor Efficacy of Dual Blockade with Encorafenib + Cetuximab in Combination with Chemotherapy in Human BRAFV600E-Mutant Colorectal Cancer
Open the PDF for Antitumor Efficacy of Dual Blockade with Encorafenib + Cetuximab in Combination with Chemotherapy in Human BRAFV600E-Mutant Colorectal Cancer in another window
Includes: Supplementary data
Journal Articles

Novel In Vitro Cancer Models for Optimizing Anti-EGFR Therapies

Stefania Napolitano, Fortunato Ciardiello
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (4): 727–729.
https://doi.org/10.1158/1078-0432.CCR-17-2937
Published: 14 February 2018
View articletitled, Novel In Vitro Cancer Models for Optimizing Anti-EGFR Therapies
Open the PDF for Novel In Vitro Cancer Models for Optimizing Anti-EGFR Therapies in another window
Journal Articles

Optimizing Anti-EGFR Therapy in Colorectal Cancer

Ramon Salazar, Fortunato Ciardiello
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (24): 5415–5416.
https://doi.org/10.1158/1078-0432.CCR-15-1768
Published: 14 December 2015
View articletitled, Optimizing Anti-EGFR Therapy in Colorectal Cancer
Open the PDF for Optimizing Anti-EGFR Therapy in Colorectal Cancer in another window
Journal Articles

SMO Gene Amplification and Activation of the Hedgehog Pathway as Novel Mechanisms of Resistance to Anti-Epidermal Growth Factor Receptor Drugs in Human Lung Cancer

Carminia Maria Della Corte, Claudio Bellevicine, Giovanni Vicidomini, Donata Vitagliano, Umberto Malapelle, Marina Accardo, Alessio Fabozzi, Alfonso Fiorelli, Morena Fasano, Federica Papaccio, Erika Martinelli, Teresa Troiani, Giancarlo Troncone, Mario Santini, Roberto Bianco, Fortunato Ciardiello, Floriana Morgillo
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2015) 21 (20): 4686–4697.
https://doi.org/10.1158/1078-0432.CCR-14-3319
Published: 14 October 2015
View articletitled, SMO Gene Amplification and Activation of the Hedgehog Pathway as Novel Mechanisms of Resistance to Anti-Epidermal Growth Factor Receptor Drugs in Human Lung Cancer
Open the PDF for SMO Gene Amplification and Activation of the Hedgehog Pathway as Novel Mechanisms of Resistance to Anti-Epidermal Growth Factor Receptor Drugs in Human Lung Cancer in another window
Includes: Supplementary data
Journal Articles

Maintenance Treatment with Cetuximab and BAY86-9766 Increases Antitumor Efficacy of Irinotecan plus Cetuximab in Human Colorectal Cancer Xenograft Models

Teresa Troiani, Stefania Napolitano, Giulia Martini, Erika Martinelli, Claudia Cardone, Nicola Normanno, Donata Vitagliano, Floriana Morgillo, Francesca Fenizia, Matilde Lambiase, Luigi Formisano, Roberto Bianco, Davide Ciardiello, Fortunato Ciardiello
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (18): 4153–4164.
https://doi.org/10.1158/1078-0432.CCR-15-0211
Published: 14 September 2015
View articletitled, Maintenance Treatment with Cetuximab and BAY86-9766 Increases Antitumor Efficacy of Irinotecan plus Cetuximab in Human Colorectal Cancer Xenograft Models
Open the PDF for Maintenance Treatment with Cetuximab and BAY86-9766 Increases Antitumor Efficacy of Irinotecan plus Cetuximab in Human Colorectal Cancer Xenograft Models in another window
Journal Articles

Primary and Acquired Resistance of Colorectal Cancer to Anti-EGFR Monoclonal Antibody Can Be Overcome by Combined Treatment of Regorafenib with Cetuximab

Stefania Napolitano, Giulia Martini, Barbara Rinaldi, Erika Martinelli, Maria Donniacuo, Liberato Berrino, Donata Vitagliano, Floriana Morgillo, Giusy Barra, Raffaele De Palma, Francesco Merolla, Fortunato Ciardiello, Teresa Troiani
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (13): 2975–2983.
https://doi.org/10.1158/1078-0432.CCR-15-0020
Published: 30 June 2015
View articletitled, Primary and Acquired Resistance of Colorectal Cancer to Anti-EGFR Monoclonal Antibody Can Be Overcome by Combined Treatment of Regorafenib with Cetuximab
Open the PDF for Primary and Acquired Resistance of Colorectal Cancer to Anti-EGFR Monoclonal Antibody Can Be Overcome by Combined Treatment of Regorafenib with Cetuximab in another window
Includes: Supplementary data
Journal Articles

Primary and Acquired Resistance of Colorectal Cancer Cells to Anti-EGFR Antibodies Converge on MEK/ERK Pathway Activation and Can Be Overcome by Combined MEK/EGFR Inhibition

Teresa Troiani, Stefania Napolitano, Donata Vitagliano, Floriana Morgillo, Anna Capasso, Vincenzo Sforza, Anna Nappi, Davide Ciardiello, Fortunato Ciardiello, Erika Martinelli
Journal: Clinical Cancer Research
Clin Cancer Res (2014) 20 (14): 3775–3786.
https://doi.org/10.1158/1078-0432.CCR-13-2181
Published: 14 July 2014
View articletitled, Primary and Acquired Resistance of Colorectal Cancer Cells to Anti-EGFR Antibodies Converge on MEK/ERK Pathway Activation and Can Be Overcome by Combined MEK/EGFR Inhibition
Open the PDF for Primary and Acquired Resistance of Colorectal Cancer Cells to Anti-EGFR Antibodies Converge on MEK/ERK Pathway Activation and Can Be Overcome by Combined MEK/EGFR Inhibition in another window
Includes: Supplementary data
Journal Articles

Increased TGF-α as a Mechanism of Acquired Resistance to the Anti-EGFR Inhibitor Cetuximab through EGFR–MET Interaction and Activation of MET Signaling in Colon Cancer Cells

Teresa Troiani, Erika Martinelli, Stefania Napolitano, Donata Vitagliano, Loreta Pia Ciuffreda, Sara Costantino, Floriana Morgillo, Anna Capasso, Vincenzo Sforza, Anna Nappi, Raffaele De Palma, Elena D'Aiuto, Liberato Berrino, Roberto Bianco, Fortunato Ciardiello
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (24): 6751–6765.
https://doi.org/10.1158/1078-0432.CCR-13-0423
Published: 16 December 2013
View articletitled, Increased TGF-α as a Mechanism of Acquired Resistance to the Anti-EGFR Inhibitor Cetuximab through EGFR–MET Interaction and Activation of MET Signaling in Colon Cancer Cells
Open the PDF for Increased TGF-α as a Mechanism of Acquired Resistance to the Anti-EGFR Inhibitor Cetuximab through EGFR–MET Interaction and Activation of MET Signaling in Colon Cancer Cells in another window
Includes: Supplementary data
Journal Articles

Synergistic Effects of Metformin Treatment in Combination with Gefitinib, a Selective EGFR Tyrosine Kinase Inhibitor, in LKB1 Wild-type NSCLC Cell Lines

Floriana Morgillo, Ferdinando Carlo Sasso, Carminia Maria Della Corte, Donata Vitagliano, Elena D'Aiuto, Teresa Troiani, Erika Martinelli, Ferdinando De Vita, Michele Orditura, Raffaele De Palma, Fortunato Ciardiello
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2013) 19 (13): 3508–3519.
https://doi.org/10.1158/1078-0432.CCR-12-2777
Published: 30 June 2013
View articletitled, Synergistic Effects of Metformin Treatment in Combination with Gefitinib, a Selective EGFR Tyrosine Kinase Inhibitor, in LKB1 Wild-type NSCLC Cell Lines
Open the PDF for Synergistic Effects of Metformin Treatment in Combination with Gefitinib, a Selective EGFR Tyrosine Kinase Inhibitor, in LKB1 Wild-type NSCLC Cell Lines in another window
Includes: Supplementary data
Journal Articles

Preclinical Activity of the Rational Combination of Selumetinib (AZD6244) in Combination with Vorinostat in KRAS-Mutant Colorectal Cancer Models

M. Pia Morelli, John J. Tentler, Gillian N. Kulikowski, Aik-Choon Tan, Erica L. Bradshaw-Pierce, Todd M. Pitts, Amy M. Brown, Sujatha Nallapareddy, John J. Arcaroli, Natalie J. Serkova, Manuel Hidalgo, Fortunato Ciardiello, S. Gail Eckhardt
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (4): 1051–1062.
https://doi.org/10.1158/1078-0432.CCR-11-1507
Published: 14 February 2012
View articletitled, Preclinical Activity of the Rational Combination of Selumetinib (AZD6244) in Combination with Vorinostat in KRAS-Mutant Colorectal Cancer Models
Open the PDF for Preclinical Activity of the Rational Combination of Selumetinib (AZD6244) in Combination with Vorinostat in KRAS-Mutant Colorectal Cancer Models in another window
Includes: Supplementary data
Journal Articles

Synergistic Antitumor Activity of Sorafenib in Combination with Epidermal Growth Factor Receptor Inhibitors in Colorectal and Lung Cancer Cells

Erika Martinelli, Teresa Troiani, Floriana Morgillo, Gabriella Rodolico, Donata Vitagliano, Maria Pia Morelli, Concetta Tuccillo, Loredana Vecchione, Anna Capasso, Michele Orditura, Ferdinando De Vita, S. Gail Eckhardt, Massimo Santoro, Liberato Berrino, Fortunato Ciardiello
Journal: Clinical Cancer Research
Clin Cancer Res (2010) 16 (20): 4990–5001.
https://doi.org/10.1158/1078-0432.CCR-10-0923
Published: 13 October 2010
View articletitled, Synergistic Antitumor Activity of Sorafenib in Combination with Epidermal Growth Factor Receptor Inhibitors in Colorectal and Lung Cancer Cells
Open the PDF for Synergistic Antitumor Activity of Sorafenib in Combination with Epidermal Growth Factor Receptor Inhibitors in Colorectal and Lung Cancer Cells in another window
Journal Articles

Vascular Endothelial Growth Factor Receptor-1 Contributes to Resistance to Anti–Epidermal Growth Factor Receptor Drugs in Human Cancer Cells

Roberto Bianco, Roberta Rosa, Vincenzo Damiano, Gennaro Daniele, Teresa Gelardi, Sonia Garofalo, Valeria Tarallo, Sandro De Falco, Davide Melisi, Roberto Benelli, Adriana Albini, Anderson Ryan, Fortunato Ciardiello, Giampaolo Tortora
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (16): 5069–5080.
https://doi.org/10.1158/1078-0432.CCR-07-4905
Published: 12 August 2008
View articletitled, Vascular Endothelial Growth Factor Receptor-1 Contributes to Resistance to Anti–Epidermal Growth Factor Receptor Drugs in Human Cancer Cells
Open the PDF for Vascular Endothelial Growth Factor Receptor-1 Contributes to Resistance to Anti–Epidermal Growth Factor Receptor Drugs in Human Cancer Cells in another window
Includes: Supplementary data
Journal Articles

Investigation of Two Dosing Schedules of Vandetanib (ZD6474), an Inhibitor of Vascular Endothelial Growth Factor Receptor and Epidermal Growth Factor Receptor Signaling, in Combination with Irinotecan in a Human Colon Cancer Xenograft Model

Teresa Troiani, Natalie J. Serkova, Daniel L. Gustafson, Thomas K. Henthorn, Owen Lockerbie, Andrea Merz, Michael Long, Mark Morrow, Fortunato Ciardiello, S. Gail Eckhardt
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (21): 6450–6458.
https://doi.org/10.1158/1078-0432.CCR-07-1094
Published: 01 November 2007
View articletitled, Investigation of Two Dosing Schedules of Vandetanib (ZD6474), an Inhibitor of Vascular Endothelial Growth Factor Receptor and Epidermal Growth Factor Receptor Signaling, in Combination with Irinotecan in a Human Colon Cancer Xenograft Model
Open the PDF for Investigation of Two Dosing Schedules of Vandetanib (ZD6474), an Inhibitor of Vascular Endothelial Growth Factor Receptor and Epidermal Growth Factor Receptor Signaling, in Combination with Irinotecan in a Human Colon Cancer Xenograft Model in another window
Journal Articles

Implication of the Insulin-like Growth Factor-IR Pathway in the Resistance of Non–small Cell Lung Cancer Cells to Treatment with Gefitinib

Floriana Morgillo, Woo-Young Kim, Edward S. Kim, Fortunato Ciardiello, Waun Ki Hong, Ho-Young Lee
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (9): 2795–2803.
https://doi.org/10.1158/1078-0432.CCR-06-2077
Published: 01 May 2007
View articletitled, Implication of the Insulin-like Growth Factor-IR Pathway in the Resistance of Non–small Cell Lung Cancer Cells to Treatment with Gefitinib
Open the PDF for Implication of the Insulin-like Growth Factor-IR Pathway in the Resistance of Non–small Cell Lung Cancer Cells to Treatment with Gefitinib in another window
Journal Articles

Synergistic Antitumor Activity of ZD6474, An Inhibitor of Vascular Endothelial Growth Factor Receptor and Epidermal Growth Factor Receptor Signaling, with Gemcitabine and Ionizing Radiation against Pancreatic Cancer

Cataldo Bianco, Elisa Giovannetti, Fortunato Ciardiello, Valentina Mey, Sara Nannizzi, Giampaolo Tortora, Teresa Troiani, Francesco Pasqualetti, Gail Eckhardt, Mario de Liguoro, Simona Ricciardi, Mario Del Tacca, David Raben, Luca Cionini, Romano Danesi
Journal: Clinical Cancer Research
Clin Cancer Res (2006) 12 (23): 7099–7107.
https://doi.org/10.1158/1078-0432.CCR-06-0833
Published: 04 December 2006
View articletitled, Synergistic Antitumor Activity of ZD6474, An Inhibitor of Vascular Endothelial Growth Factor Receptor and Epidermal Growth Factor Receptor Signaling, with Gemcitabine and Ionizing Radiation against Pancreatic Cancer
Open the PDF for Synergistic Antitumor Activity of ZD6474, An Inhibitor of Vascular Endothelial Growth Factor Receptor and Epidermal Growth Factor Receptor Signaling, with Gemcitabine and Ionizing Radiation against Pancreatic Cancer in another window
Journal Articles

Novel Toll-Like Receptor 9 Agonist Induces Epidermal Growth Factor Receptor (EGFR) Inhibition and Synergistic Antitumor Activity with EGFR Inhibitors

Vincenzo Damiano, Rosa Caputo, Roberto Bianco, Francesco P. D'Armiento, Antonio Leonardi, Sabino De Placido, A. Raffaele Bianco, Sudhir Agrawal, Fortunato Ciardiello, Giampaolo Tortora
Journal: Clinical Cancer Research
Clin Cancer Res (2006) 12 (2): 577–583.
https://doi.org/10.1158/1078-0432.CCR-05-1943
Published: 20 January 2006
View articletitled, Novel Toll-Like Receptor 9 Agonist Induces Epidermal Growth Factor Receptor (EGFR) Inhibition and Synergistic Antitumor Activity with EGFR Inhibitors
Open the PDF for Novel Toll-Like Receptor 9 Agonist Induces Epidermal Growth Factor Receptor (EGFR) Inhibition and Synergistic Antitumor Activity with EGFR Inhibitors in another window
Journal Articles

Cooperative Antitumor Effect of Multitargeted Kinase Inhibitor ZD6474 and Ionizing Radiation in Glioblastoma

Vincenzo Damiano, Davide Melisi, Cataldo Bianco, David Raben, Rosa Caputo, Gabriella Fontanini, Roberto Bianco, Anderson Ryan, A. Raffaele Bianco, Sabino De Placido, Fortunato Ciardiello, Giampaolo Tortora
Journal: Clinical Cancer Research
Clin Cancer Res (2005) 11 (15): 5639–5644.
https://doi.org/10.1158/1078-0432.CCR-05-0174
Published: 01 August 2005
View articletitled, Cooperative Antitumor Effect of Multitargeted Kinase Inhibitor ZD6474 and Ionizing Radiation in Glioblastoma
Open the PDF for Cooperative Antitumor Effect of Multitargeted Kinase Inhibitor ZD6474 and Ionizing Radiation in Glioblastoma in another window
Journal Articles

A Meta-Analysis on the Interaction between HER-2 Expression and Response to Endocrine Treatment in Advanced Breast Cancer

Michele De Laurentiis, Grazia Arpino, Erminia Massarelli, Angela Ruggiero, Chiara Carlomagno, Fortunato Ciardiello, Giampaolo Tortora, Diego D'Agostino, Francesca Caputo, Giuseppe Cancello, Emilia Montagna, Luca Malorni, Luigia Zinno, Rossella Lauria, Angelo Raffaele Bianco, Sabino De Placido
Journal: Clinical Cancer Research
Clin Cancer Res (2005) 11 (13): 4741–4748.
https://doi.org/10.1158/1078-0432.CCR-04-2569
Published: 06 July 2005
View articletitled, A Meta-Analysis on the Interaction between HER-2 Expression and Response to Endocrine Treatment in Advanced Breast Cancer
Open the PDF for A Meta-Analysis on the Interaction between HER-2 Expression and Response to Endocrine Treatment in Advanced Breast Cancer in another window
Journal Articles

Antitumor Activity of ZD6474, a Vascular Endothelial Growth Factor-2 and Epidermal Growth Factor Receptor Small Molecule Tyrosine Kinase Inhibitor, in Combination with SC-236, a Cyclooxygenase-2 Inhibitor

Concetta Tuccillo, Marco Romano, Teresa Troiani, Erika Martinelli, Floriana Morgillo, Ferdinando De Vita, Roberto Bianco, Gabriella Fontanini, Raffaele A. Bianco, Giampaolo Tortora, Fortunato Ciardiello
Journal: Clinical Cancer Research
Clin Cancer Res (2005) 11 (3): 1268–1276.
https://doi.org/10.1158/1078-0432.1268.11.3
Published: 11 February 2005
View articletitled, Antitumor Activity of ZD6474, a Vascular Endothelial Growth Factor-2 and Epidermal Growth Factor Receptor Small Molecule Tyrosine Kinase Inhibitor, in Combination with SC-236, a Cyclooxygenase-2 Inhibitor
Open the PDF for Antitumor Activity of ZD6474, a Vascular Endothelial Growth Factor-2 and Epidermal Growth Factor Receptor Small Molecule Tyrosine Kinase Inhibitor, in Combination with SC-236, a Cyclooxygenase-2 Inhibitor in another window
Journal Articles

The Effects of Cetuximab Alone and in Combination With Radiation and/or Chemotherapy in Lung Cancer

David Raben, Barb Helfrich, Daniel C. Chan, Fortunato Ciardiello, LiMin Zhao, Wilbur Franklin, Anna E. Barón, Chan Zeng, Tim K. Johnson, Paul A. Bunn, Jr
Journal: Clinical Cancer Research
Clin Cancer Res (2005) 11 (2): 795–805.
https://doi.org/10.1158/1078-0432.795.11.2
Published: 08 February 2005
View articletitled, The Effects of Cetuximab Alone and in Combination With Radiation and/or Chemotherapy in Lung Cancer
Open the PDF for The Effects of Cetuximab Alone and in Combination With Radiation and/or Chemotherapy in Lung Cancer in another window